64
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Pharmacotherapy of polycythemia vera

, &
Pages 977-985 | Published online: 28 Oct 2013
 

Abstract

Introduction: Polycythemia vera (PV) is a clonal myeloproliferative neoplasm associated with arterial and/or venous thromboses and long-term risks of leukemic or myelofibrotic transformation.

Areas covered: The authors discuss the state-of-the-art treatment for PV, including the choice of hematocrit target, the use of aspirin and prescription of hydroxyurea, interferon and other cytoreductive agents. This review highlights current areas of need and discusses how pegylated forms of interferon and Janus kinase inhibitors may fit into the treatment armamentarium.

Expert opinion: Recent advances in treatment have reduced the risk of major thromboses or cardiovascular death to ∼ 1% per year. In contrast, the risk of leukemic or myelofibrotic transformation remains ever present, and this risk becomes increasingly relevant as thrombosis-related morbidity and mortality decline. Future therapies will need to demonstrate an impact on malignant clone size, and/or on the risk of disease transformation, if further survival prolongations are to be achieved.

Notes

This box summarizes key points contained in the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.